Higher HDL-C Linked to Cardiac Risk With LDL-C <;2.0 mmol/L

Increased risk for cardiovascular events and all-cause mortality for patients with type 2 diabetes

plaque in artery

FRIDAY, May 27, 2016 (HealthDay News) -- For patients with type 2 diabetes with low-density lipoprotein cholesterol (LDL-C) levels <2.0 mmol/L, higher high-density lipoprotein cholesterol (HDL-C) is associated with increased risk for cardiovascular events and all-cause mortality, according to a study published online May 23 in Diabetes Care.

Shahnam Sharif, M.D., from the University Medical Center Utrecht in the Netherlands, and colleagues performed a prospective cohort study of 1,829 patients with type 2 diabetes in the Second Manifestations of ARTerial disease (SMART) cohort. The authors examined the risk of HDL-C on cardiovascular events and all-cause mortality. Analyses were performed in strata of LDL-C levels and lipid-lowering therapy intensity.

The researchers found that during a median follow-up of 7.0 years there were 335 new cardiovascular events and 385 deaths. Plasma HDL-C was not related to cardiovascular events (hazard ratio [HR], 0.97; 95 percent confidence interval [CI], 0.93 to 1.01) or all-cause mortality (HR, 0.99; 95 percent CI, 0.96 to 1.03). The effect was modified by plasma LDL-C levels: For patients with LDL-C levels <2.0 mmol/L, higher HDL-C was associated with higher risk of all-cause mortality (HR, 1.14; 95 percent CI, 1.07 to 1.21) and higher risk for cardiovascular events (HR, 1.10; 95 percent CI, 1.07 to 1.21), compared with patients with LDL-C levels between 2.0 and 2.5 mmol/L or >2.5 mmol/L.

"Future studies are needed to confirm this finding and investigate the causality," the authors write.

Full Text (subscription or payment may be required)

Physician’s Briefing Staff

Physician’s Briefing Staff

Published on May 27, 2016

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ